Vascular normalization: study examines how antiangiogenesis therapies work.
Webb
Tracy
T
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015687:Cell Hypoxia / Q000187:drug effects; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000517:prevention & control; D013997:Time Factors; D014183:Transplantation, Heterologous; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000187:drug effects*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D040301:Vascular Endothelial Growth Factor Receptor-2